Marker Therapeutics (MRKR) Other Accumulated Expenses (2010 - 2026)

Marker Therapeutics (MRKR) has reported Other Accumulated Expenses for 17 consecutive years, with $1.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Other Accumulated Expenses rose 143.41% year-over-year to $1.0 million; the TTM figure through Mar 2026 stood at $1.0 million (up 143.41% YoY), while the FY2024 annual figure was $1.7 million, up 28.61% from the prior year.
• Other Accumulated Expenses grew to $1.0 million in Q1 2026 per MRKR's latest filing, from $328315.0 in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $1.7 million in Q4 2024 and bottomed at $38000.0 in Q4 2022.
• Historically, Other Accumulated Expenses has averaged $548027.5 across 5 years, with a median of $341157.5 in 2024.
• Annual changes were most pronounced in 2022 — Other Accumulated Expenses sank 84.8% — and 2023, when it surged 3400.0%.
• Marker Therapeutics' Other Accumulated Expenses stood at $38000.0 in 2022, then soared by 3400.0% to $1.3 million in 2023, then rose by 28.61% to $1.7 million in 2024, then tumbled by 80.81% to $328315.0 in 2025, then jumped by 204.96% to $1.0 million in 2026.
• Business Quant data shows MRKR's Other Accumulated Expenses at $1.0 million in Q1 2026, $328315.0 in Q3 2025, and $656631.0 in Q2 2025.